If you live with herpes, you've probably heard the same three medication names for years: acyclovir, valacyclovir and famciclovir. On October 9, 2026, the U.S. Food and Drug Administration added a new one to the list. The FDA approved Hovilpri (pritelivir) tablets, an oral antiviral that attacks the herpes simplex virus (HSV) in a different way than the drugs most people know.

The manufacturer, Asahi Kasei Therapeutics, described it in its October 13 announcement as the first FDA-approved HSV therapy with a new mechanism of action in nearly 30 years. That's real news. But the approval is also narrow, and it's easy to misread headlines about a "new herpes drug." Here's what was approved, who it's for, and what it does (and doesn't) change if you're dating with herpes, HIV or both.

What the FDA actually approved

According to the FDA's announcement, Hovilpri is approved for adults with weakened immune systems who have mucocutaneous HSV lesions (sores on the skin or mucous membranes, such as the lips, nostrils, eyes or genitals) that have not responded to acyclovir, valacyclovir or famciclovir.

A few key points:

• It treats both HSV-1 and HSV-2, including strains resistant to the older drugs, according to Asahi Kasei Therapeutics' announcement.
• It's a pill. The approved dose is 400 mg on day one, then 100 mg once a day, according to the FDA-approved prescribing information (drug label).
• It's not a cure. The label states plainly that because HSV establishes lifelong latent infection, treatment is not curative.
• It isn't on pharmacy shelves yet. The company says it expects Hovilpri to be available in the U.S. before the end of 2026.

Why a "new mechanism" matters

Acyclovir and its relatives need a viral enzyme called thymidine kinase to switch on. When the virus mutates that enzyme, those drugs can stop working well, as Asahi Kasei Therapeutics explains in its announcement. And when resistance develops, it usually spans the whole family: CDC's STI Treatment Guidelines note that all acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir.

For acyclovir-resistant genital herpes, CDC's guidelines name IV foscarnet as the treatment of choice, and describe foscarnet and cidofovir as nephrotoxic (kidney-harming) drugs that require intensive lab monitoring and infectious-disease specialist input. Pritelivir is a helicase-primase inhibitor. It blocks a different part of the machinery the virus uses to copy itself, and the FDA prescribing information says cross-resistance with acyclovir, penciclovir or foscarnet is not likely.

What the trial found

The approval rests on the Phase 3 PRIOH-1 trial (Part C). According to the FDA prescribing information:

• 101 immunocompromised adults were randomized: 51 to pritelivir and 50 to "investigator's choice" treatment. In the comparison group, most people (70%) got IV foscarnet. The rest received topical imiquimod, IV cidofovir or topical cidofovir.
• Participants had a range of conditions that weaken the immune system, including blood cancers or disorders (47%), stem-cell transplants (40%), HIV (38%) and autoimmune or inflammatory diseases (29%).
• By day 28, all lesions had healed in 63% of people on pritelivir, compared with 34% in the comparison group.
• By day 42, healing rates were 82% vs. 42%.

On safety, Asahi Kasei Therapeutics reports that adverse reactions happened less often with pritelivir (22% vs. 54%), as did stopping treatment because of side effects (2% vs. 20%). The most common side effect was headache (6% vs. 4%).

Keep the limits in mind, too. The study was open-label, meaning participants and doctors knew who got which treatment, and it was relatively small. It tested a specific, hard-to-treat group, not everyone with herpes.

Why this matters for people living with HIV

Herpes and HIV overlap a lot. The World Health Organization (WHO) says in its herpes fact sheet that HSV-2 is among the most common infections in people living with HIV, and that in immunocompromised people, including those with advanced HIV, herpes can cause more severe symptoms and more frequent recurrences. CDC's guidelines add that HIV treatment (ART) reduces how severe and frequent genital herpes symptoms are.

So for most people, this approval doesn't change day-to-day care. Acyclovir, valacyclovir and famciclovir remain the recommended options in CDC's guidelines. Hovilpri is specifically for lesions that haven't responded to them. Still, if you're immunocompromised and have dealt with a stubborn outbreak that just wouldn't heal, it's worth knowing that an oral option is on the way.

One practical note: the FDA prescribing information flags drug interactions. Certain acid reducers, including some proton pump inhibitors, can lower pritelivir levels, and pritelivir can raise levels of some other medicines. If you take ART or other daily medications, make sure your provider and pharmacist see your full list.

What it doesn't change (yet) for dating with herpes

It's tempting to read "new herpes drug" as "new way to protect partners." That isn't what was approved.

It's not approved for routine outbreaks or transmission

An earlier Phase 2 study, published in the New England Journal of Medicine in 2014, tested pritelivir for 28 days in 156 otherwise healthy people with genital HSV-2. At the 75 mg daily dose, viral shedding was detected on 2.1% of days, compared with 16.6% on placebo. Days with sores also dropped, from 9.0% to 1.2%. Those are encouraging signals, but that study didn't measure transmission to partners. Today's approval doesn't cover people with healthy immune systems or routine outbreaks.

Your current toolkit still works

The tools you already have are well studied. According to CDC:

• Daily suppressive therapy cuts recurrences by 70% to 80% in people who get frequent outbreaks.
• Valacyclovir 500 mg a day lowers HSV-2 transmission in mixed-status heterosexual couples.
• Condoms used consistently and correctly reduce, but don't eliminate, the risk of transmission.

We break down how daily antivirals fit into dating in our guide to suppressive therapy for herpes.

One nuance if you live with both HIV and herpes: CDC's guidelines say suppressive antivirals in people with HIV and HSV haven't been shown to reduce HSV-2 transmission to partners. Talk with your provider about the right mix of strategies for you and your partner.

U=U is still the headline for HIV

For HIV itself, the most powerful fact hasn't changed. CDC's HIV treatment-as-prevention guidance states that a person with HIV who takes HIV medicine as prescribed and gets and stays virally suppressed or undetectable will not transmit HIV to sex partners. CDC also points out that being undetectable doesn't protect against other STIs. Our explainer on undetectable viral load and what U=U means for dating covers that in depth.

More is in the pipeline

Pritelivir is one of several approaches researchers are exploring. If you're following the science, see our coverage of the ABI-5366 trial results.

Questions worth bringing to your provider

• "My outbreaks sometimes don't heal on my current medication. Could that be resistance, and should it be tested?"
• "Am I considered immunocompromised for the purposes of this approval?"
• "Do any of my current medications, including acid reducers, interact with pritelivir?"
• "What's the best plan to lower transmission risk for my partner, given my HIV and HSV status?"

The bigger picture

Herpes is incredibly common. The WHO's herpes fact sheet estimates that 520 million people aged 15 to 49 have HSV-2, and 3.8 billion people under 50 have HSV-1. Even so, by the manufacturer's account, this is the first new mechanism of action approved for HSV in nearly 30 years. A new class of antiviral reaching approval, even for a narrow group, shows that herpes research is moving.

None of this changes your worth as a partner. You deserve honest information, good care and a relationship where you can talk about all of it openly. If you're getting ready for that conversation, our guide on what to say when you disclose HSV is a good place to start. And when you're ready to meet people who get it, MeetPositives has dedicated communities for herpes dating and HIV dating.

---

This article is for general information only and isn't medical advice. Talk with a qualified healthcare provider about your diagnosis, medications and treatment options.